PANLAR - ACR Review Course
PANLAR – ACR Review Course
Wednesday 10 August – 10 to 15:45 hrs
Module 1:
- 10:00 – Opening Statement – Douglas White (Moderator)
- 10:10 – Update on Rheumatoid Arthritis: Are We Close to Prevent It? – Ozlem Pala
- 10:50 – ANCA Associated Vasculitis – Anisha Dua
11:30 – 11:40 Break
Module 2:
- 11:40 – Immune Related Adverse Events from Cancer Immunotherapy; a Primer for the Rheumatologist – Anne Bass
- 12:20 – Diagnosing and Treating Scleroderma: What’s New? - Francesco Boin
13:15 – 14:15 Break
Module 3:
- 14:15 - Updates in SLE: Overview of New Therapies – Alfred Kim
- 14:55 - Osteoporosis: Bone of Contention 2022 – Kenneth Saag
- 15:35 Closing Statement – Douglas White (Moderator)
Faculty








Assistant Professor of Clinical Medicine at the University of Miami Miller School of Medicine since 2010, leads patient care, teaching, and research activities in Rheumatology. Dr. Pala is board certified in both Internal Medicine and Rheumatology. She recently completed her MSPH training in 2022 and interested in studying complementary approaches to improve well-being of rheumatology patients.

Douglas White, MD, PhD is the Chair of Rheumatology at Gundersen Health System and Clinical Adjunct Assistant Professor at the University of Wisconsin School of Medicine and Public Health. He currently serves as President-elect of the American College of Rheumatology and on the board of directors of the Local Lupus Alliance.

Anisha B. Dua MD, MPH is an Associate Professor of Medicine, Rheumatology Fellowship Program Director, and Director of the Vasculitis Center at Northwestern University. She is on the Board of Directors for the Vasculitis Foundation, a member of the Scientific Advisory Council for the Rheumatology Research Foundation, and Chair of the ACR In-Training-Exam committee.

Dr. Saag is Professor of Medicine and holds the Jane Knight Lowe Endowed Chair in the Division and the Department of Medicine at the University of Alabama at Birmingham (UAB). He became Division Director of Clinical Immunology and Rheumatology in July 2020. His research focuses on comparative effectiveness and safety of therapeutics as well as methods to improve quality of care in gout and osteoporosis. He is also Director of the UAB Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center. He has been a practicing physician with UAB Medicine and researcher in the UAB School of Medicine since 1998.

Dr. Kim is an adult rheumatologist at Barnes-Jewish Hospital and an Assistant Professor of Medicine at Washington University School of Medicine. Dr. Kim founded and directs the Washington University Lupus Clinic engaging in both clinical care of patients with lupus and heading a large research program focused on clinical and translational projects related to systemic lupus erythematosus. More recently, he started the “COVID-19 Vaccine Responses in Patients with Autoimmune Diseases” (COVaRiPAD) study, which seeks to elucidate the strength, quality, durability, evolution, and safety of COVID-19 vaccine responses in patients who take immunosuppressives for autoimmune diseases.

Dr. Francesco Boin is the Chief of the Division of Rheumatology and the Director of the Scleroderma Program in the Kao Autoimmunity Institute at the Cedars-Sinai Medical Center in Los Angeles (California). He is Professor of Medicine at Cedars-Sinai as well as at the University of California Los Angeles (UCLA).
Dr. Boin is an accomplished clinician and investigator with extensive experience in the diagnosis and treatment of scleroderma and other fibrosing skin disorders. His research is focused on the genetic risk and the role of immune cells in the pathogenesis of scleroderma and lung complications. He has been involved with teaching and mentoring medical students, residents, and post-doctoral fellows throughout his academic career.

Dr. Bass is a Professor of Clinical Medicine at Weill Cornell Medicine/Hospital for Special Surgery (HSS) in New York City. She is a practicing rheumatologist at HSS, New York Presbyterian Hospital (Cornell), and Memorial Sloan Kettering Cancer Center. She co-directs a large checkpoint inhibitor-associated arthritis registry at HSS and leads a multidisciplinary team doing translational studies in that cohort. Her research goals are to identify effective treatments for immune related adverse events (irAE) that preserve anti-tumor responses, and to gain insight into the development of de novo rheumatic diseases, such as rheumatoid arthritis, through the study of irAE.